<DOC>
	<DOC>NCT03086239</DOC>
	<brief_summary>This is a Japanese, multicenter, open-label, dose-escalation study. This is the first study to assess the safety and tolerability as well as explore the pharmacokinetics, pharmacodynamics and antitumor activity of rovalpituzumab tesirine in Japanese participants with advanced small cell lung cancer (SCLC).</brief_summary>
	<brief_title>A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Histologically or cytologically confirmed advanced, recurrent smallcell lung cancer (SCLC) with documented disease progression after at least two (2) prior systemic regimens, including at least one (1) platinumbased regimen. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate hematologic, hepatic and renal function. No prior exposure to a pyrrolobenzodiazepine (PBD)based drug.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced, Recurrent Small Cell Lung Cancer</keyword>
	<keyword>Rovalpituzumab tesirine</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Cancer</keyword>
</DOC>